NOTE
9 – NON-CONTROLLING INTEREST
As
of December 31, 2025 and 2024, the Company had a majority interest in ViralClear of 69.74% and 69.08%, respectively. As of December 31,
2025 and 2024, the Company had a majority interest in of BioSig AI of 84.5% for both years.
A
reconciliation of ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. non-controlling loss attributable to the Company:
Net
loss attributable to the non-controlling interest for the year ended December 31, 2025 (000’s):
SCHEDULE OF NON-CONTROLLING INTEREST
| | |
ViralClear | | |
BioSig AI | | |
|
|
| | |
Pharmaceuticals, Inc. | | |
Sciences, Inc. | | |
Total |
|
| | |
(000’s) | | |
(000’s) | | |
(000’s) |
|
| Net income | |
$ | - | | |
$ | 95 | | |
$ |
95 |
|
| Average Non-Controlling interest percentage of losses | |
| 30 | % | |
| 16 | % | |
|
16 |
% |
| Net income attributable to non-controlling interest | |
$ | - | | |
$ | 15 | | |
$ |
15 |
|
Net
loss attributable to the non-controlling interest for the year ended December 31, 2024 (000’s):
| | |
ViralClear | | |
BioSig AI | | |
|
|
| | |
Pharmaceuticals, Inc. | | |
Sciences, Inc. | | |
Total |
|
| | |
(000’s) | | |
(000’s) | | |
(000’s) |
|
| Net income (loss) | |
$ | (41 | ) | |
$ | 24 | | |
$ |
(17) |
|
| Average Non-Controlling interest percentage of profit/losses | |
| 32 | % | |
| 16 | % | |
|
52 |
% |
| Net income (loss) attributable to non-controlling interest | |
$ | (13 | ) | |
$ | 4 | | |
$ |
(9) |
|
The
following table summarizes the changes in non-controlling interest for the year ended December 31, 2025 (000’s):
SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST
| | |
ViralClear | | |
BioSig AI | | |
|
|
| | |
Pharmaceuticals, Inc. | | |
Sciences, Inc. | | |
Total |
|
| | |
(000’s) | | |
(000’s) | | |
(000’s) |
|
| Balance, January 1, 2025 | |
$ | (171 | ) | |
$ | 188 | | |
$ |
17 |
|
| Net income attributable to non-controlling interest | |
| - | | |
| 15 | | |
|
15 |
|
| Balance, December 31, 2025 | |
$ | (171 | ) | |
$ | 203 | | |
$ |
32 |
|
The
following table summarizes the changes in non-controlling interest for the year ended December 31, 2024 (000’s):
| | |
ViralClear | | |
BioSig AI | | |
|
|
| | |
Pharmaceuticals, Inc. | | |
Sciences, Inc. | | |
Total |
|
| | |
(000’s) | | |
(000’s) | | |
(000’s) |
|
| Balance, January 1, 2024 | |
$ | (158 | ) | |
$ | 184 | | |
$ |
26 |
|
| Balance | |
$ | (158 | ) | |
$ | 184 | | |
$ |
26 |
|
| Net income (loss) attributable to non-controlling interest | |
| (13 | ) | |
| 4 | | |
|
(9) |
|
| Balance, December 31, 2024 | |
$ | (171 | ) | |
$ | 188 | | |
$ |
17 |
|
| Balance | |
$ | (171 | ) | |
$ | 188 | | |
$ |
17 |
|
| | |
| | | |
| | | |
|
|
|
|